Rowland & Co. Investment Counsel ADV lowered its holdings in shares of Clorox Co (NYSE:CLX) by 14.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,170 shares of the company’s stock after selling 536 shares during the period. Rowland & Co. Investment Counsel ADV’s holdings in Clorox were worth $472,000 as of its most recent SEC filing.
A number of other large investors have also modified their holdings of the stock. Vanguard Group Inc. boosted its stake in Clorox by 2.6% during the 2nd quarter. Vanguard Group Inc. now owns 14,534,634 shares of the company’s stock worth $1,936,595,000 after purchasing an additional 369,918 shares during the period. Parnassus Investments CA boosted its stake in Clorox by 1.7% during the 3rd quarter. Parnassus Investments CA now owns 4,451,150 shares of the company’s stock worth $587,151,000 after purchasing an additional 76,236 shares during the period. Renaissance Technologies LLC boosted its stake in Clorox by 24.5% during the 2nd quarter. Renaissance Technologies LLC now owns 1,341,400 shares of the company’s stock worth $178,728,000 after purchasing an additional 263,700 shares during the period. Ameriprise Financial Inc. boosted its stake in Clorox by 24.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 1,341,272 shares of the company’s stock worth $178,433,000 after purchasing an additional 265,200 shares during the period. Finally, Janus Henderson Group PLC boosted its stake in Clorox by 8,008.5% during the 2nd quarter. Janus Henderson Group PLC now owns 1,323,475 shares of the company’s stock worth $176,340,000 after purchasing an additional 1,307,153 shares during the period. Hedge funds and other institutional investors own 73.14% of the company’s stock.
Shares of Clorox Co (CLX) traded down $2.44 during trading on Thursday, reaching $141.99. 1,192,026 shares of the company’s stock were exchanged, compared to its average volume of 777,451. The stock has a market cap of $18,310.00, a P/E ratio of 26.05, a P/E/G ratio of 3.84 and a beta of 0.42. The company has a debt-to-equity ratio of 3.02, a quick ratio of 0.77 and a current ratio of 1.10. Clorox Co has a 52 week low of $118.41 and a 52 week high of $150.40.
The business also recently declared a quarterly dividend, which will be paid on Friday, February 9th. Stockholders of record on Wednesday, January 24th will be issued a $0.84 dividend. The ex-dividend date of this dividend is Tuesday, January 23rd. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.37%. Clorox’s dividend payout ratio is presently 61.65%.
A number of analysts recently weighed in on the stock. Deutsche Bank assumed coverage on shares of Clorox in a research note on Wednesday, December 13th. They set a “hold” rating and a $142.00 price target for the company. Royal Bank of Canada reiterated a “hold” rating and set a $115.00 price target on shares of Clorox in a research note on Sunday, October 8th. Jefferies Group reiterated a “hold” rating and set a $130.00 price target on shares of Clorox in a research note on Wednesday, December 13th. Bank of America upgraded shares of Clorox from an “underperform” rating to a “neutral” rating and set a $155.00 price objective for the company in a research report on Thursday, January 4th. Finally, Wells Fargo & Co restated a “hold” rating and set a $130.00 price objective on shares of Clorox in a research report on Wednesday, December 13th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have given a buy rating to the company. Clorox presently has an average rating of “Hold” and an average price target of $134.33.
In other news, SVP Michael R. Costello sold 10,574 shares of the stock in a transaction dated Tuesday, November 28th. The shares were sold at an average price of $136.01, for a total value of $1,438,169.74. Following the completion of the transaction, the senior vice president now owns 34,867 shares in the company, valued at approximately $4,742,260.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Matthew T. Laszlo sold 20,051 shares of the stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $130.46, for a total transaction of $2,615,853.46. Following the completion of the transaction, the senior vice president now owns 10,896 shares of the company’s stock, valued at approximately $1,421,492.16. The disclosure for this sale can be found here. Company insiders own 1.00% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Markets Daily and is owned by of Markets Daily. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.themarketsdaily.com/2018/01/12/rowland-co-investment-counsel-adv-sells-536-shares-of-clorox-co-clx.html.
The Clorox Company is a manufacturer and marketer of consumer and professional products. The Company sells its products primarily through mass retail outlets, e-commerce channels, wholesale distributors and medical supply distributors. The Company operates through four segments: Cleaning, Household, Lifestyle and International.
Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clorox Co (NYSE:CLX).
Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.